Overall, across all anchors and drugs, there was no statistical imbalance for synergism for any of the major cancer driver genotypes, including KRAS, PIK3CA, EGFR, STK11. Interestingly, among KRAS mutant cell lines, STK11 (encoding LKB1) mutant cell lines were seen to harbor more synergies than STK11 WT ones. The gene discussed is PIK3CA; the disease is cancer.